Compare EDBL & OGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | EDBL | OGEN |
|---|---|---|
| Founded | 2020 | 1996 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Farming/Seeds/Milling | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.6M | 3.6M |
| IPO Year | N/A | 2010 |
| Metric | EDBL | OGEN |
|---|---|---|
| Price | $3.37 | $0.69 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 229.5K | 178.1K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 82.57 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $29.56 | N/A |
| Revenue Next Year | $20.00 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.15 | $0.11 |
| 52 Week High | $7.54 | $9.16 |
| Indicator | EDBL | OGEN |
|---|---|---|
| Relative Strength Index (RSI) | 70.20 | 42.15 |
| Support Level | $3.25 | $0.62 |
| Resistance Level | $3.98 | $0.72 |
| Average True Range (ATR) | 0.64 | 0.07 |
| MACD | 0.04 | -0.00 |
| Stochastic Oscillator | 43.66 | 34.09 |
Edible Garden AG Inc is a next-generation controlled environment agriculture farming company. It uses traditional agricultural growing techniques together with technology to grow fresh, organic food, sustainably and safely while improving traceability. The company uses the controlled environment of traditional greenhouse structures, such as glass greenhouses together with hydroponic and vertical greenhouses to sustainably grow organic herbs and lettuces.
Oragenics Inc is engaged in the research and development of nasal delivery pharmaceutical medications in neurology and fighting infectious diseases. The company's product ONP-002 is a fully synthetic, non-naturally occurring neurosteroid, is lipophilic, and can cross the blood-brain barrier to rapidly reduce swelling, oxidative stress and inflammation while restoring proper blood flow through gene amplification. The Company operates in one reportable segment, which includes activities related to advancing the development of its concussion drug, ONP-002.